RCUS

Arcus Biosciences, Inc. RCUS

NYSEMid CapHealthcare

13F Pro quality score

Rank #2,617 of 2,925

Why it scores 26Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$41.00M

Quarter to Jun 30

Net income

$-91.00M

Quarter to Jun 30

Free cash flow

$-119.00M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$3.78B total
GILEAD SCIENCES, INC.
$968.83M0.0%
BlackRock, Inc.
$506.11M+7.8%
STATE STREET CORP
$185.89M+11.4%
WELLINGTON MANAGEMENT GROUP LLP
$181.76M-3.2%
SUVRETTA CAPITAL MANAGEMENT, LLC
$147.26M-5.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$137.98M+4.8%
FMR LLC
$124.85M+247.5%
VANGUARD CAPITAL MANAGEMENT LLC
$119.88M+0.8%
CITADEL ADVISORS LLC
$96.65M+135.7%
Woodline Partners LP
$92.73M-20.4%
GEODE CAPITAL MANAGEMENT, LLC
$75.51M+8.7%
Siren, L.L.C.
$74.62M-19.5%
Fisher Asset Management, LLC
$65.96M-2.3%
MARSHALL WACE, LLP
$59.97M-48.3%
SAMLYN CAPITAL, LLC
$47.70M-18.9%
DIMENSIONAL FUND ADVISORS LP
$44.22M+0.6%
BNP Paribas Asset Management Holding S.A.
$43.76M-14.2%
GOLDMAN SACHS GROUP INC
$42.78M+38.8%
Soleus Capital Management, L.P.
$36.03M+158.6%
Sofinnova Ventures Inc
$29.16M+2.4%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$29.03M+4.2%
NORTHERN TRUST CORP
$28.75M+11.0%
Parkman Healthcare Partners LLC
$28.34M-23.9%
Invesco Ltd.
$26.06M+3.0%
BAKER BROS. ADVISORS LP
$26.05M+103.3%
See all 231 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RCUS

Earnings Per Share

13fpro.ai/company/RCUS

Loading ratio trend…

RCUS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Arcus Biosciences, Inc.'s annual filings on SEC EDGAR.

Arcus Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$247.0M$-353.0M-156.3%
FY 2024$258.0M$-283.0M-127.9%
FY 2023$117.0M$-307.0M—
FY 2022$112.0M$-267.0M—
FY 2021$383.0M$53.0M14.1%
FY 2020$78.0M$-123.0M-159.0%
Source: RCUS filings on SEC EDGAR →

Companies similar to RCUS

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

RCUS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Arcus Biosciences, Inc. (RCUS): stock profile, AI score and financials

Arcus Biosciences, Inc. (RCUS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCUS at 25.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,617 of 2,925 stocks — the bottom half of the AI-ranked universe. RCUS scores in the top quartile across revenue growth (88.9). Areas of concern include free cash flow (3.4) and profitability (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcus Biosciences, Inc. reports quarterly revenue of $41.0M, net income of $-91.0M, free cash flow of $-119.0M. Top institutional holders of RCUS by reported 13-F value include GILEAD SCIENCES, BlackRock, STATE STREET, based on the most recent SEC filings. RCUS trades on the NYSE exchange and files with the SEC under CIK 1724521. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcus Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1724521 →